

INVIVO THERAPEUTICS HOLDINGS CORP.

Form 8-K

January 18, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 or 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**JANUARY 11, 2012**

**Date of Report (Date of earliest event reported)**

**INVIVO THERAPEUTICS HOLDINGS CORP.**

**(Exact Name of Registrant as Specified in Charter)**

**NEVADA**  
**(State or Other Jurisdiction)**

**000-52089**  
**(Commission)**

**36-4528166**  
**(IRS Employer)**

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

of Incorporation)

File Number)  
One Broadway, 14<sup>th</sup> Floor

Identification No.)

Cambridge, Massachusetts 02142

(Address of Principal Executive Offices) (Zip Code)

(617) 475-1520

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e) On January 11, 2012, the Governance, Nominating and Compensation Committee of the Board of Directors of InVivo Therapeutics Holdings Corp. (the Company ) approved a cash bonus payment of \$230,000 to Frank Reynolds, Chief Executive Officer and Chief Financial of the Company, pursuant to his cash bonus plan for fiscal year 2011.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVO THERAPEUTICS HOLDINGS CORP.

Date: January 18, 2012

By: /s/ Frank M. Reynolds  
Frank M. Reynolds  
Chief Executive Officer